Published in Cancer Weekly, December 7th, 1998
This virus, ONYX-838, is genetically engineered to replicate in and destroy tumor cells that have defects in the retinoblastoma (RB) gene pathway. Defects in the RB gene pathway are present in virtually all human cancers.
"The RB-targeted virus showed substantial efficacy in several mouse tumor models," said David H. Kirn, MD, Onyx. Kirn presented the results at the Seventh International Conference on Gene Therapy of Cancer, held in San Diego,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.